ADMA Biologics Presents Late-Breaking Poster Presentation Highlighting Clinical Utility of S. Pneumoniae Hyperimmune Globulin...
27 February 2021 - 12:00AM
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an
end-to-end commercial biopharmaceutical company dedicated to
manufacturing, marketing and developing specialty plasma-derived
biologics, today announced the presentation of a late-breaking
poster at the 2021 American Academy of Allergy, Asthma &
Immunology Conference (“AAAAI”) Virtual Annual Meeting taking place
February 26 – March 1, 2021. The abstract has been published online
in a supplement to The Journal of Allergy and Clinical Immunology.
“Vulnerable patient populations, including the immune
compromised, remain at risk of S. pneumoniae infection despite the
availability of FDA-approved vaccines,” said Adam Grossman,
President and Chief Executive Officer of ADMA. “These data
underscore the exciting prospect of bridging the time between
vaccination and seroconversion to achieve protective levels of
antibody with a targeted, plasma derived hyperimmune globulin to
ensure protection against infection for at-risk patients in
hospital and outpatient settings. Our existing intellectual
property portfolio includes issued patents on the composition of
matter and methods of use for producing a standardized hyperimmune
globulin targeted to the most common 23 serotypes of S. pneumoniae
bacteria. We will continue to evaluate opportunities to expand our
pipeline and future product offerings to maximize value for our
shareholders and to address the unmet needs of our targeted patient
populations.”
Details for the AAAAI 2021 presentation are as
follows:
Abstract Title: Results of
Cross-Stakeholder Qualitative Study on the Potential Utility of a
Hyperimmune Globulin for the Prophylaxis/Treatment for S.
Pneumoniae Infection in Vulnerable Populations
Author: Gruenglas, et al.Session
Title: Poster Abstract SessionsSession
Dates: Friday, February 26 – Monday, March 1,
2021Session Location: Virtual Poster
HallPoster No: L30
A PDF copy of the abstract can be accessed here.
About ADMA Biologics,
Inc.
ADMA Biologics is an end-to-end American
commercial biopharmaceutical company dedicated to manufacturing,
marketing and developing specialty plasma-derived biologics for the
treatment of immunodeficient patients at risk for infection and
others at risk for certain infectious diseases. ADMA currently
manufactures and markets three United States Food and Drug
Administration (FDA) approved plasma-derived biologics for the
treatment of immune deficiencies and the prevention of certain
infectious diseases: BIVIGAM® (immune globulin intravenous, human)
for the treatment of primary humoral immunodeficiency (PI);
ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for
the treatment of PI; and NABI-HB® (hepatitis B immune globulin,
human) to provide enhanced immunity against the hepatitis B virus.
ADMA manufactures its immune globulin products at its FDA-licensed
plasma fractionation and purification facility located in Boca
Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also
operates as an FDA-approved source plasma collector in the U.S.,
which provides a portion of its blood plasma for the manufacture of
its products. ADMA’s mission is to manufacture, market and develop
specialty plasma-derived, human immune globulins targeted to niche
patient populations for the treatment and prevention of certain
infectious diseases and management of immune compromised patient
populations who suffer from an underlying immune deficiency, or who
may be immune compromised for other medical reasons. ADMA has
received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793
and 10,259,865 related to certain aspects of its products and
product candidates. For more information, please visit
www.admabiologics.com.
Forward-Looking Statements
Any statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, including, but not
limited to, statements regarding the expansion of our product
pipeline and future product offerings. Such statements are
identified by use of the words “anticipates,” “believes,”
“estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,”
“should,” and similar expressions. Any forward-looking statements
contained herein are based on current expectations, but are subject
to risks and uncertainties that could cause actual results to
differ materially from those indicated, including, but not limited
to, the effectiveness of the rights plan in providing the Board of
Directors with time to make informed decisions that are in the best
long-term interests of ADMA and its stockholders, and other risk
factors discussed from time to time in our filings with the SEC,
including those factors discussed under the caption “Risk Factors”
in our most recent annual report on Form 10-K, filed with the SEC
on March 13, 2020, and in subsequent reports filed with or
furnished to the SEC. ADMA assumes no obligation and does not
intend to update these forward-looking statements, except as
required by law, to reflect events or circumstances occurring after
today’s date.
COMPANY CONTACT:Skyler BloomDirector, Investor
Relations and Corporate Strategy | 201-478-5552 |
sbloom@admabio.com
INVESTOR RELATIONS CONTACT:Sam MartinManaging
Director, Argot Partners | 212-600-1902 | sam@argotpartners.com
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Apr 2024 to May 2024
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From May 2023 to May 2024